Navigation Links
Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors
Date:5/16/2013

1 Receptor Agonist Product Portfolios and R&D Pipelines

 

4 ) Interferon

a) INTERFERON alpha

 

• Interferon alpha sales 2012 of branded products in regulated markets

• 1st generation Interferon alpha-2a in regulated markets

• 1st generation Interferon alpha-2a in non-regulated markets

• Next generation Interferon alpha-2a in regulated markets

• Next generation Interferon alpha-2a in non-regulated markets and biosimilars

• 1st generation Interferon alpha-2b in regulated markets

• 1st generation Interferon alpha-2b in non-regulated markets and biosimilars

• Next generation Interferon alpha-2b in regulated markets

• Next generation Interferon alpha-2b in non-regulated markets and biosimilars

• Other Interferon alpha sub-types

• Interferon alpha with not specified sub-type – 1/2

• Purified natural human interferon alpha

 

b) Consensus INTERFERONs

c) INTERFERON beta

 

• Interferon beta sales 2012 of branded products in regulated markets

• 1st generation Interferon beta-1a in regulated markets

• 1st generation Interferon beta-1a in non-regulated markets and biosimilars

• 1st generation Interferon beta-1b in regulated markets

• 1st generation Interferon beta-1b in non-regulated markets and biosimilars

• 1st generation Interferon beta with not disclosed sub-type

• Next generation Interferon beta in regulated markets

• Purified natural human interferon beta

 

d) INTERFERON gamma

e) Other INTERFERONs

5 ) Insulin

 

• 2012 Sales of branded recombinant human insulins in regulated markets

• 2012 Sales of branded short-acting recombinant human insulin analogs in regulate
'/>"/>

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Cell Therapeutics to Present at Upcoming Investor Conferences
2. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
3. ASGCT Annual Meeting to Highlight Latest Advances in Genetic and Cellular Therapeutics
4. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
5. Emergent Technologies and Caisson Biotech Form Strategic Alliance with Local Health Care Providers to Improve Delivery and Performance of a Therapeutic Drug
6. Henri A. Termeer Joins Moderna Therapeutics Board Of Directors
7. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
8. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
9. Cell Therapeutics to Report First Quarter Financial Results after Market on May 2, 2013
10. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
11. Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 2014  Atlanta-based Intellimedix could make a positive ... of Ebola by suggesting a new, computational approach ... Center for Computational Systems Biology have spent years ... uses for existing drugs through systematic repurposing, and ... bout against Ebola. Logo - ...
(Date:10/30/2014)... Global polyvinyl chloride (PVC) demand registered a ... 2008-2009, especially in North America and Europe. However, the ... to a growing trend. , The largest chunk of ... construction segment. In 2013, the key PVC application spheres ... rigid film. Moreover, the PVC was consumed in the ...
(Date:10/30/2014)... October 30, 2014 Rancho BioSciences ... they have manually curated public data source TCGA ... customers. the data is now available for other ... unifies public and internal data sources for their Pharma, ... out of the data that becomes more easily accessible. ...
(Date:10/30/2014)... Avure Technologies celebrates a year of success ... of its fleet of high volume High Pressure Processing (HPP) ... we return to PackExpo this year, which is where we ... said Jeff Williams, CEO at Avure. “Sales of the new ... be meeting the challenges of market demand for higher throughput. ...
Breaking Biology Technology:Atlanta-Based Intellimedix May Help Solve Ebola With Computer Algorithms 2Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 2Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 3Rancho BioSciences Manually Curated TCGA Data Sets Available 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3
... Jan. 17 Peptimmune, Inc., a privately,held biotechnology ... close,of $8.2 million of a Series D preferred ... Enterprise Associates, MPM Capital, Hunt Ventures,L.P., Boston Medical ... as,certain other investors, including its Chairman of the ...
... at Cleveland Clinic Brings Extensive Experience, in the Use of ... ... Cardiovascular Disease, ST. LOUIS, Jan. 17 Stereotaxis, Inc. ... as Chief Medical Officer. Dr. Burkhardt was most recently the,Associate ...
... ON, Jan. 17 /PRNewswire-FirstCall/ - YM BioSciences Inc.,(AMEX: ... oncology company that identifies,develops and commercializes differentiated products ... a letter from the U.S. Food and Drug,Administration ... Acute Pain,Study (AP5) of AeroLEF(TM) for which FDA ...
Cached Biology Technology:Peptimmune Announces First Close of Series D Private Financing 2Peptimmune Announces First Close of Series D Private Financing 3Stereotaxis Appoints David Burkhardt, M.D. as Chief Medical Officer 2Stereotaxis Appoints David Burkhardt, M.D. as Chief Medical Officer 3YM BioSciences provides update on AeroLEF(TM) clinical development program 2YM BioSciences provides update on AeroLEF(TM) clinical development program 3
(Date:10/30/2014)... 2014 Biological membranes are mainly composed of lipid ... solution ions onto lipid membranes helps clarify functional ... provides a quantitative description of the equilibria between ... and Zbigniew Figaszewski from the University of Bialystok, ... these findings, just published in EPJ E ...
(Date:10/29/2014)... released by unconventional oil and gas production are well ... in the open access journal Environmental Health . ... found. The study is the first to be based ... sites and could be used to supplement official air-quality ... reserves that do not readily flow to the surface. ...
(Date:10/29/2014)... study of its kind to date, researchers have used ... the risk for autism. Joseph Buxbaum, Ph.D., Icahn School ... Daly, Ph.D., Broad Institute of Harvard and MIT, and ... affected children, parents and unrelated people. They identified changes ... the risk for autism spectrum disorder (ASD) – a ...
Breaking Biology News(10 mins):Ion adsorption matter in biology 2Air quality and unconventional oil and gas sites 2Air quality and unconventional oil and gas sites 3
... is hard to fool the brain by providing it with ... driven to a great extent by the amount of energy ... sugars compared to artificial sweeteners. Professor Ivan de Araujo, ... USA, says:,"The consumption of high-calorie beverages is a major contributor ...
... The digestive systems of all animals contain a large number ... provide warmth, shelter and food to a vast range of ... hosts or at least cause no ill effects other than ... have been associated with disease. Among them is Helicobacter ...
... machinery necessary to assemble proteins, the building blocks of ... DNA is first transcribed to messenger RNA in the ... are put in motion to translate the code into ... been demonstrated that the ribosome is far more than ...
Cached Biology News:The brain cannot be fooled by artificial sweeteners 2Getting rid of unwanted visitors 2Global analysis reveals new insights into the ribosome -- with important implications for disease 2Global analysis reveals new insights into the ribosome -- with important implications for disease 3Global analysis reveals new insights into the ribosome -- with important implications for disease 4
... cocktail of 3 siRNAs specifically targeted to ... popular product. The siTrio reagent guarantees you ... target gene when used under standard conditions ... of optimal transfection with one of B-Bridges ...
... This kit #27295 has improved stability and ... improved kit not only has overcome this problem ... first, we have changed the formulation of HRP ... X 1). By this change, the stability of ...
... kit is a complete assay system for ... in human serum or plasma. The assay ... in the IDS 1,25D RIA followed by ... with ready to use reagents, no organic ...
Rabbit polyclonal to L Kynurenine ( Abpromise for all tested applications). Antigen: Synthetic peptide L Kynurenine conjugated to a protein carrier. Entrez Gene ID: 8942 Swiss Protein ID...
Biology Products: